GBI 0.00% 16.0¢ genera biosystems limited

gbi valuation - part 2, page-3

  1. 371 Posts.
    Bochie that jump in sales is mainly a function of screening sales taking off.

    Realisticaly it will take GBI a few years to build up a reasonable set of data (marketing material) for screening sales to become meaningful...that number in 2012 assumes a PapType market share of 10% of screening tests and 50% of Australia & NZ markets.

    In screening market 2010 market share assumed is 2% whilst 2011 is 4%.

    The ASCUS/triage sales from 2010-2011 are the low hanging fruit so to speak and can get GBI profitable whilst building the data for the larger screening market.

    cheers
 
watchlist Created with Sketch. Add GBI (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.